The first long COVID study conducted in South Africa found that 82% of patients still had persistent or new symptoms a month after their discharge from hospital. However, much is still unknown about what exactly causes this and how to alleviate the suffering, which is becoming an increasing health burden across the globe. Elsabé Brits surveyed the latest evidence and asked local experts to place it in context.
Outbreaks of hospital-acquired infections such as Klebsiella have claimed the lives of infants and made headlines on a number of occasions over the last decade. Tiyese Jeranji looks at how the germs involved spread, how common these infections are, and what can be done to prevent outbreaks.
Cryptococcal meningitis is the second biggest killer of people living with HIV after tuberculosis (TB). Now, a global initiative, the Ending Cryptococcal Meningitis Deaths by 2030 Strategic Framework aims to get the gold standard drug to treat cryptococcal meningitis – flucytosine – registered in countries that need it. Amy Green reports.
An experimental COVID-19 vaccine currently in Phase I trials being run by the University of Cape Town has a unique design that might allow it to offer better protection against current and future variants of the SARS-CoV-2 virus. Elri Voigt provides an update on the trial and unpacks the science behind this vaccine candidate.
It has been over a year since the world saw the first confirmed case of COVID-19, yet the science behind the virus’ physical impact on children remains relatively unclear. Kathryn Cleary spoke to two experts in paediatrics and immunology to get an update on what we have learnt so far.
We know antiretroviral therapy can prevent HIV infection, but can natural biological substances do the same? The results of a recent scientific trial have answered this question: Yes, using broadly neutralising antibodies. But what are broadly neutralising antibodies? How do they work? And when will the average person get access to them? Amy Green breaks down the science.
South Africa is set to produce its first vaccine in 25 years, but it won’t be a COVID-19 jab. Plans are however in place to “fill and finish” COVID-19 vaccines in South Africa. Laura Lopez Gonzalez has the details.
While progress in the race for effective COVID-19 vaccines has been rapid and impressive, an effective HIV vaccine remains elusive. As part of Spotlight’s World AIDS Day 2020 coverage, Kathryn Cleary asks two of South Africa’s top vaccine researchers to update us on where we are in the race for an HIV vaccine.
Immunity to COVID-19 is much more interesting and much more complicated than simply something you do or do not have. Kathryn Cleary spoke to two experts about what we know about COVID-19 immunity and the implications of that for antibody testing and the development of vaccines.